ArticleOncoTargets and therapy2018

Combination chemotherapy with Zyflamend reduced the acquired resistance of bladder cancer cells to cisplatin through inhibiting NFκB signaling pathway.

Yanshi Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.